Raquel Rodríguez-Acebes

Dr. Raquel Rodríguez-Acebes

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
PLPatricia Gema Cruz Lopez
Patricia Gema Cruz Lopez
RRRogelio Fernández Rodríguez
Rogelio Fernández Rodríguez
RRRaquel Rodríguez-Acebes
Raquel Rodríguez-Acebes
MDMarta Martinez Diez
Marta Martinez Diez
GSGema Santamaria
Gema Santamaria
CCCarmen Cuevas
Carmen Cuevas
PM742 (1), a new chemical entity, has been isolated from the sponge Discodermia du Bocage collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of action, which led us to conduct an extensive Structure-Activity-Relationship study through the synthesis of different analogs. As a result, a derivatively named PM534 (2) is currently in its first human Phase I clinical trial. Herein, we present a comprehensive review of the isolation, structural elucidation, and antitumor activities of the parent compound PM742.

7 May 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MMMaría Jesús Martín
María Jesús Martín
JHJuan Hernando
Juan Hernando
RRRaquel Rodríguez-Acebes
Raquel Rodríguez-Acebes
AGAsier Gómez-SanJuan
Asier Gómez-SanJuan
AFAndres Francesch
Andres Francesch
CCCarmen Cuevas
Carmen Cuevas
We report the first total synthesis of PM742 using N-Boc-D-Norvaline and 2-Methyl-L-Cysteine hydrochloride as starting materials in a convergent sequence of eight chemical steps. This strategy provides efficient access to PM742 and enables the preparation of structurally related analogs. PM742 exhibited in vitro cytotoxic activity against a panel of human tumor cell lines, which prompted preliminary structure-activity relationship (SAR) studies. These efforts led to the preparation of PM534, a related analog with improved activity that has now entered Phase I clinical trials in humans.